Chia Tai Tianqing's TQB2102 Doubles Progression-Free Survival in HER2-Low Breast Cancer Phase III
Start here
Chia Tai Tianqing, a core subsidiary of Sino Biopharmaceutical, has reported pivotal Phase III results for its independently developed HER2-directed antibody-drug conjugate TQB2102 in HER2-low breast cancer, selected as a late-breaking abstract for a proffered paper session at ESMO. The trial showed a median progression-free survival of 16.4 months with TQB2102 versus 5.5 months with comparator chemotherapy, an approximately 71% reduction in the risk of disease progression or death, and a 2.2% incidence of treatment-related ILD. The data position TQB2102 as a potential competitor in a field where trastuzumab deruxtecan has set the benchmark, though questions of full survival data, regulatory filing timelines, and comparative efficacy remain open.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickChia Tai Tianqing Reports Phase III Results for TQB2102 in HER2-Low Breast Cancer at ESMO
Chia Tai Tianqing, a core subsidiary of Sino Biopharmaceutical, reported pivotal Phase III results for its independently developed TQB2102 in HER2-low breast cancer, selected as a late-breaking abstract for a proffered paper session at ESMO. The abstract showed a median progression-free survival of 16.4 months with TQB2102 versus 5.5 months with comparator chemotherapy, an approximately 71% reduction in risk of disease progression or death, and a 2.2% incidence of treatment-related ILD.
- mp.weixin.qq.comChia Tian Qing's TQB2102 Succeeds in Late-Stage HER2-Low Breast Cancer Study, mPFS 16.4 Months
Chia Tian Qing's TQB2102 met its endpoint in a late-stage study in HER2-low breast cancer, with a median progression-free survival of 16.4 months versus 5.5 months in the chemotherapy control group. The risk of disease progression or death fell by about 71%, and treatment-related interstitial lung disease occurred in 2.2% of patients. Results were presented at the 2026 ESMO annual meeting.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 23 19:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.